Migraine treatment without injection passes clinical trials

NEW YORK Results from two clinical studies presented at this year’s American Headache Society meeting could help a needle-free migraine drug from Zogenix get Food and Drug Administration approval.

The drug, sumatriptan, uses DosePro technology to enter the subcutaneous layer of the skin. The first study found the drug is as effective as when injected into the thigh or abdomen with GlaxoSmithKline’s Imitrex STATdose, which does use a needle.

The second study had patients using sumatriptan DosePro at home as the primary way of treating migraines. Ninety-eight percent of patients were able to use it correctly as migraine attacks took place.